1. Pink Sheet
  2. >>Biosimilars & Generics

Advances On the Biosimilar Litigation Battlefield

 
• By Brenda Sandburg

A look at the evolution of litigation, from Amgen's 'bold' at-risk launch of Herceptin and Avastin biosimilars to the jump in settlements, new battles over manufacturing information and an expected petition to the Supreme Court.

Medieval battle scene with cavalry and infantry on chessboard. Chess board game concept of business ideas and competition and strategy ideas Chess figures on a dark background with smoke and fog. - Image
Biosimilar makers and innovators are fighting over host of issues.

Amgen Inc.'s at-risk launch of biosimilar versions of Herceptin and Avastin last month was a jolt to the biosimilar community. Not only does Amgen face the threat of huge damages if it loses infringement battles with Genentech Inc., but the court's rationale for denying a preliminary injunction could change the dynamic of the patent dance.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Biosimilars & Generics